Total Payments
$7,628
2024 Payments
$1,969
Companies
48
Transactions
474
Medicare Patients
3,126
Medicare Billing
$579,216
Payment Breakdown by Category
Food & Beverage$7,605 (99.7%)
Education$23.16 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,605 | 469 | 99.7% |
| Education | $23.16 | 5 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $845.81 | 70 | $0 (2022) |
| Supernus Pharmaceuticals, Inc. | $780.89 | 29 | $0 (2024) |
| ABBVIE INC. | $757.38 | 58 | $0 (2024) |
| SK Life Science, Inc. | $725.45 | 52 | $0 (2024) |
| UCB, Inc. | $710.63 | 46 | $0 (2024) |
| NEUROPACE, INC. | $564.69 | 13 | $0 (2023) |
| Lundbeck LLC | $351.94 | 27 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $235.47 | 15 | $0 (2021) |
| PFIZER INC. | $223.05 | 13 | $0 (2024) |
| LivaNova USA, Inc. | $190.37 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,969 | 107 | Supernus Pharmaceuticals, Inc. ($488.13) |
| 2023 | $1,164 | 74 | AbbVie Inc. ($191.04) |
| 2022 | $1,333 | 76 | NEUROPACE, INC. ($325.96) |
| 2021 | $824.26 | 59 | SK Life Science, Inc. ($186.98) |
| 2020 | $328.81 | 20 | Sunovion Pharmaceuticals Inc. ($118.21) |
| 2019 | $707.73 | 44 | Sunovion Pharmaceuticals Inc. ($188.12) |
| 2018 | $719.90 | 50 | Sunovion Pharmaceuticals Inc. ($243.08) |
| 2017 | $580.94 | 44 | Sunovion Pharmaceuticals Inc. ($222.74) |
All Payment Transactions
474 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $16.17 | General |
| Category: NEUROLOGY | ||||||
| 12/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: PAIN | ||||||
| 12/11/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $14.76 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 11/22/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $16.37 | General |
| 11/19/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $15.80 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 11/18/2024 | Aucta Pharmaceuticals, Inc. | Motpoly XR (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: Central Nervous System | ||||||
| 11/14/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/12/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: EPILEPSY | ||||||
| 11/11/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Neurology | ||||||
| 11/11/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $2.11 | General |
| Category: Neurology | ||||||
| 11/06/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: PAIN | ||||||
| 11/05/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Food and Beverage | Cash or cash equivalent | $14.83 | General |
| Category: NEUROLOGY | ||||||
| 11/04/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 11/04/2024 | AQUESTIVE THERAPEUTICS, INC. | LIBERVANT (Drug) | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: Central Nervous System | ||||||
| 11/01/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: NEUROLOGY | ||||||
| 10/29/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $16.55 | General |
| Category: NEUROLOGY | ||||||
| 10/28/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $14.41 | General |
| 10/18/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: NEUROSCIENCE | ||||||
| 10/16/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: PAIN | ||||||
| 10/15/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $17.00 | General |
| 10/10/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $9.84 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 09/25/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Neurology | ||||||
| 09/23/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 753 | 1,192 | $737,470 | $145,271 |
| 2022 | 11 | 793 | 1,214 | $537,365 | $141,091 |
| 2021 | 14 | 885 | 1,341 | $648,784 | $170,949 |
| 2020 | 14 | 695 | 1,028 | $497,515 | $121,905 |
Total Patients
3,126
Total Services
4,775
Medicare Billing
$579,216
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2023 | 132 | 276 | $181,554 | $48,927 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 221 | 361 | $168,088 | $35,691 | 21.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 146 | $43,800 | $15,199 | 34.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 40 | 48 | $29,814 | $7,194 | 24.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 121 | 124 | $117,296 | $6,039 | 5.1% |
| 95700 | Measurement of brain wave activity (eeg), continuous | Office | 2023 | 26 | 27 | $20,520 | $5,614 | 27.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 16 | 16 | $33,174 | $5,568 | 16.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 36 | $27,000 | $5,310 | 19.7% |
| 95718 | Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | Facility | 2023 | 45 | 45 | $20,883 | $5,215 | 25.0% |
| 95708 | Measurement of brain wave activity (eeg), 12-26 hours | Office | 2023 | 17 | 36 | $54,000 | $4,491 | 8.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 40 | $10,000 | $2,769 | 27.7% |
| 95721 | Measurement of brain wave activity (eeg), 37-60 hours with health care professional review and report | Office | 2023 | 11 | 11 | $7,997 | $1,982 | 24.8% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2023 | 26 | 26 | $23,344 | $1,273 | 5.5% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2022 | 130 | 257 | $166,454 | $46,577 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 241 | 360 | $93,223 | $35,646 | 38.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 65 | 173 | $43,250 | $15,212 | 35.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 66 | 81 | $21,039 | $10,327 | 49.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 134 | 137 | $56,107 | $6,663 | 11.9% |
| 95708 | Measurement of brain wave activity (eeg), 12-26 hours | Office | 2022 | 22 | 50 | $72,979 | $5,983 | 8.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 36 | $25,200 | $5,956 | 23.6% |
| 95700 | Measurement of brain wave activity (eeg), continuous | Office | 2022 | 31 | 31 | $23,560 | $5,669 | 24.1% |
| 95718 | Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | Facility | 2022 | 35 | 35 | $15,925 | $4,045 | 25.4% |
| 95721 | Measurement of brain wave activity (eeg), 37-60 hours with health care professional review and report | Office | 2022 | 15 | 15 | $10,853 | $2,598 | 23.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 21 | 39 | $8,775 | $2,413 | 27.5% |
| 95720 | Continuous measurement of brain wave activity with video (veeg), 12-26 hours, with health care professional analysis, interpretation and report | Facility | 2021 | 94 | 220 | $142,780 | $40,364 | 28.3% |
About Dr. Andy Rodriguez, MD
Dr. Andy Rodriguez, MD is a Epilepsy healthcare provider based in Livingston, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/26/2010. The National Provider Identifier (NPI) number assigned to this provider is 1972820330.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andy Rodriguez, MD has received a total of $7,628 in payments from pharmaceutical and medical device companies, with $1,969 received in 2024. These payments were reported across 474 transactions from 48 companies. The most common payment nature is "Food and Beverage" ($7,605).
As a Medicare-enrolled provider, Rodriguez has provided services to 3,126 Medicare beneficiaries, totaling 4,775 services with total Medicare billing of $579,216. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Epilepsy
- Other Specialties Neurology, Clinical Neurophysiology
- Location Livingston, NJ
- Active Since 04/26/2010
- Last Updated 04/10/2024
- Taxonomy Code 2084E0001X
- Entity Type Individual
- NPI Number 1972820330
Products in Payments
- APTIOM (Drug) $1,004
- Briviact (Drug) $489.91
- Qelbree (Drug) $488.13
- QULIPTA (Drug) $466.91
- RNS Neurostimulator Kit (Device) $442.14
- UBRELVY (Drug) $270.30
- NURTEC ODT (Drug) $250.19
- AFINITOR (Drug) $197.05
- VYEPTI (Biological) $189.38
- QELBREE (Drug) $170.18
- ONFI (Drug) $162.56
- Fycompa (Drug) $135.58
- VALTOCO (Drug) $130.37
- EMGALITY (Drug) $126.49
- VNS Therapy (Device) $124.87
- RNS System (Device) $122.55
- VYVANSE (Drug) $102.03
- FYCOMPA (Drug) $94.80
- ZTLido (Drug) $94.61
- OXTELLAR XR (Drug) $92.84
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.